Table 1.

Baseline characteristics of guselkumab-randomized patients

	Guselkumab Q4W (N = 245)	Guselkumab Q8W (N = 248)	Pooled Guselkumab (N = 493)
Age, years	45.9 (11.5)	44.9 (11.9)	45.4 (11.7)
Male sex, n (%)	142 (58%)	129 (52%)	271 (55%)
Race, n (%)
White  Asian	242 (99%) 3 (1%)	240 (97%) 8 (3%)	482 (98%) 11 (2%)
BMI, kg/m2  Normal (< 18.5–<25 kg/m2), n (%)  Overweight (25–<30 kg/m2), n (%)  Obese (≥ 30 kg/m2), n (%)	29.1 (5.9) 66 (26.9%) 83 (33.9%) 96 (39.2%)	28.7 (6.3) 74 (29.8%) 82 (33.1%) 92 (37.1%)	28.9 (6.1) 140 (28.4%) 165 (33.5%) 188 (38.1%)
PsA duration, years	5.5 (5.9)	5.1 (5.5)	5.3 (5.7)
SJC (0–66)	12.9 (7.8)	11.7 (6.8)	12.3 (7.4)
TJC (0–68)	22.4 (13.5)	19.8 (11.9)	21.1 (12.8)
HAQ-DI score (0–3)	1.2 (0.6)	1.3 (0.6)	1.3 (0.6)
PtGA– arthritis VAS (0–10 cm)	6.4 (1.9)	6.5 (1.9)	6.5 (1.9)
Pt Pain VAS (0–10 cm)	6.2 (2.0)	6.3 (2.0)	6.2 (2.0)
PASI score (0–72)	10.8 (11.7)	9.7 (11.7)	10.2 (11.7)
Enthesitis, n (%)  LEI score	170 (69%) 3.0 (1.7)	158 (64%) 2.6 (1.5)	328 (67%) 2.8 (1.6)
FACIT-Fatigue score	30.8 (9.6)	29.3 (9.9)	30.0 (9.8)
Medical history of depression, n (%)	4 (1.6%)	4 (1.6%)	8 (1.6%)
Suicidal ideation (eC-SSRS), n (%)*	3 (1.2%)	6 (2.4%)	9 (1.8%)
Medical history of fibromyalgia, n (%)	2 (0.8%)	1 (0.4%)	3 (0.6%)

Data are presented as mean (standard deviation) unless stated otherwise

BMI = body mass index; eC-SSRS = electronic Columbia-Suicidality Severity Rating Scale; FACIT = Functional Assessment of Chronic Illness Therapy; HAQ-DI = Health Assessment Questionnaire-Disability Index; LEI = Leeds enthesitis index; PASI = Psoriasis Area Severity Index; PsA = psoriatic arthritis; Pt = patient; PtGA = patient global assessment; Q4W = every 4 weeks; Q8W = every 8 weeks; SJC = swollen joint count; TJC = tender joint count; VAS = visual analog scale

*Patients with unstable suicidal ideation/behavior who were at risk were excluded from DISCOVER-2